Compare Regeneron Pharmaceuticals Inc (REGN) vs First Trust Cloud Computing ETF (SKYY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs First Trust Cloud Computing ETF — how do they compare? Regeneron Pharmaceuticals Inc trades at $808.33 (market cap $83.15B), while First Trust Cloud Computing ETF trades at $158.14. The key difference: Regeneron Pharmaceuticals Inc pays a 0.47% dividend while First Trust Cloud Computing ETF pays none. Which is the better fit depends on your goals.
| REGN | SKYY | |
|---|---|---|
Market Cap | $83.15B | — |
Sector | Health | — |
52-Week High | $852.03 | $168.91 |
52-Week Low | $555.51 | $104.16 |
Enterprise Value | $77.86B | — |
Dividend Yield | 0.47% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% on the day, with a bullish technical signal from moving averages and a neutral RSI near 54. The stock shows strong profitability with a net income margin of 27.86% and consistent earnings beats in recent quarters. However, multiple class-action lawsuits filed in September 2026 allege securities fraud related to a Phase 3 clinical trial disclosure, creating near-term uncertainty.
The outlook remains cautiously optimistic given robust fundamentals and a 69% analyst buy rating, but legal overhangs and a projected earnings dip in 2026 pose risks. Upside hinges on legal resolution and pipeline execution, while downside is capped by institutional support like CalSTRS' recent $79 billion position increase.
SKYY, the First Trust Cloud Computing ETF, trades at $159.62, down 1.2% today, with a neutral technical signal. It offers diversified exposure to cloud infrastructure and software, benefiting from AI adoption and digital transformation trends. Recent news highlights strong infrastructure spending and AI demand driving cloud computing growth, positioning SKYY for potential long-term gains.
The outlook for SKYY is positive due to secular trends in cloud migration and AI, though risks include market volatility and sector concentration. Analyst sentiment is cautiously optimistic, with institutional interest supporting the ETF's role in technology sector allocations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About First Trust Cloud Computing ETF
The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index is designed to track the performance of companies involved in the cloud computing industry.
Read more on SKYY →
